Clinical Trials Logo

Filter by:
NCT ID: NCT04088396 Recruiting - Clinical trials for Systemic Juvenile Idiopathic Arthritis

A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Start date: February 12, 2020
Phase: Phase 3
Study type: Interventional

The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA). Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive baricitinib or tocilizumab reference. In cohort 2, participants will receive baricitinib.

NCT ID: NCT04088279 Recruiting - Clinical trials for Pulmonary Hypertension

Novel Quantitative Magnetic Resonance Imaging (MRI) Measures in the Assessment and Follow-up of Patients With Pulmonary Hypertension (PH)

Start date: November 19, 2018
Phase: N/A
Study type: Interventional

A prospective study of the use of two novel MRI techniques (oxygen-enhanced and fourier decomposition MRI) in the initial diagnosis and follow-up of patients with Pulmonary Hypertension. The investigators believe these techniques may present a novel set of imaging biomarkers that may be used for risk stratification, prediction of treatment response and longitudinal disease monitoring. The reserach MRI is in addition to standard of care and will not affect treatment decisions.

NCT ID: NCT04086134 Recruiting - Clinical trials for Constipation - Functional

Physiological, Microbiological and Metabolomic Effects of Fruit Products

Start date: October 25, 2019
Phase: N/A
Study type: Interventional

This study is a randomised, parallel group, controlled trial, comparing the effects of fruit products as to their physiological, microbiologic and metabolomic effects on the gut, as well as their effects on the dietary intake and quality in healthy people with constipation.

NCT ID: NCT04085939 Recruiting - Fall Patients Clinical Trials

Referral to Pharmacists - Ambulance Clinician Experience Survey

REPLACES
Start date: September 30, 2019
Phase:
Study type: Observational

Falls in people aged 65 years and over are a common reason for calling the emergency ambulance service. Falls can be serious, with about 1 in 20 people having to be taken to hospital because they have been injured. Thankfully, in more than 4 out of 10 cases, people are not seriously injured and can be left at home. However, it is important that the reason for the fall is found and future falls are prevented where possible. Yorkshire Ambulance Service can already make a referral to another local service to get specialist practical help for falls prevention when people are left at home after a fall. Research has shown that the safe use of medicines can prevent future falls, but that did not form. Now a new service has been set up for Yorkshire Ambulance Service to refer patients to the Leeds General Practice (GP) Confederation. A pharmacist working in the patients GP surgery will undertake a review of the patient's use of their medicines. However, it is unknown how ambulance staff identify patients who may be at risk of future falls due to medicines being taken or issues with medicines management at home. This data is not currently collected in any ambulance patient records. It is also not known what their current practice is when a patient who is not managing their medicines well is identified. A literature search has revealed no papers on this topic. This research survey seeks to understand how ambulance clinicians identify and assist patients who are having difficulty in managing their medicines. Therefore, the results of this study are likely to provide new knowledge which will be generalisable to United Kingdom (UK) ambulance service practice.

NCT ID: NCT04085211 Recruiting - Clinical trials for Inflammatory Bowel Diseases

Image-Enhanced Endoscopy in the Gastrointestinal Tract

Start date: July 1, 2019
Phase:
Study type: Observational

This study evaluates a range of endoscopic image enhancement techniques for assessing conditions involving the gastrointestinal tract. This study aims to determine: (i) the accuracy of different techniques to diagnose or grade severity of several gastrointestinal conditions (ii) if image-enhancement techniques could potentially replace investigations currently used in daily practice (e.g. biopsy) with a view to reduce costs and shorten the interval to initiate treatment

NCT ID: NCT04084782 Recruiting - Clinical trials for Onychomycosis of Toenail

An Internet Mediated Research Study to Assess the Quality of Life of Consumers With Self-reported Fungal Nail Infection (Onychomycosis) During Treatment With Scholl Fungal Nail.

Start date: August 13, 2019
Phase:
Study type: Observational

To evaluate the effect on quality of life of consumers with self-reported onychomycosis during the first 4 weeks of treatment in relation to the appearance of the infected toenail.

NCT ID: NCT04083599 Recruiting - Melanoma Clinical Trials

GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors

Start date: September 17, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the safety and anti-tumor activity of GEN1042 in patients with metastatic or locally advanced solid tumors.

NCT ID: NCT04081428 Recruiting - Prostate Cancer Clinical Trials

Using Breath, Cell Free DNA and Image Analysis to PRedIct Normal TissUe and Tumour Response During Prostate Cancer SBRT

PRINToUT
Start date: October 11, 2018
Phase:
Study type: Observational

Personalisation of radiotherapy dose based on real-time assessments of normal tissue and tumour response would maximise cure and minimise treatment related toxicity. During a 5 fraction course of prostate Stereotactic Body Radiotherapy (SBRT) this pilot study will assess whether a number of different biomarker approaches can predict for normal tissue and tumour response. Firstly the investigators will analyse volatile organic compounds released within the breath with each fraction of treatment. Secondly the investigators will analyse cell free normal tissue and tumour DNA released during treatment. Thirdly the investigators will develop imaging processing algorithms to look for imaging biomarkers predicting rectal wall toxicity using pre and post treatment cone beam CT verification images. Each of these approaches will be assessed against prostate specific antigen (PSA), Common Terminology Criteria for Adverse Events (CTCAE v4.0) criteria and Expanded Prostate Cancer Index Composite (EPIC-26) patient reported outcomes with a maximum of 24 months of follow up.

NCT ID: NCT04079348 Recruiting - Wounds and Injuries Clinical Trials

Oasis Donor Site Wounds Post-Market Study

Start date: November 1, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate the safety and performance of Oasis extracellular matrix (ECM) when used as a treatment for donor site wounds in the United Kingdom. Oasis ECM is commercially available for the treatment of partial and full-thickness skin wounds, including chronic wounds, wounds from trauma, and wounds that occur during surgery, such as donor site wounds. The ability of the Oasis ECM to promote the healing of donor site wounds will be evaluated in this study. About 40 patients (20 in each arm) over 16 years old will be involved in this study at one center in the United Kingdom.

NCT ID: NCT04079166 Recruiting - Melanoma (Skin) Clinical Trials

SCIB1 in Melanoma Patients Receiving Either Nivolumab With Ipilimumab or Pembrolizumab (The SCOPE Study)

Start date: August 19, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out if a new treatment cancer vaccine called SCIB1 can be used safely when added to either nivolumab (Opdivo) with ipilimumab (Yervoy) or pembrolizumab (Keytruda), standard treatments approved for patients with advanced melanoma (skin cancer). The study will also look to see if SCIB1 can increase the likelihood that melanoma patients will respond to either nivolumab with ipilimumab or pembrolizumab, and also if SCIB1 can help to make those responses last longer. SCIB1 is considered experimental. SCIB1 has been given to melanoma patients in an earlier study. It was generally well-tolerated, and researchers saw some signs that it may help to stimulate the immune system, which is a way in which the body can fight the cancer.